D. E. Shaw & Co., Inc. Biotechnology

D. E. Shaw & Co., Inc.

$156 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ETNB 89bio, Inc.	$690M	$883,000 0.0% of portfolio	60,208	Q3 2025 New
ABUS Arbutus Biopharma Corp	$678M	$862,000 0.0% of portfolio	189,952	Q3 2025 Added 366.71%
AKRO Akero Therapeutics, Inc.	$2.52B	$834,000 0.0% of portfolio	17,572	Q3 2025 Reduced 67.38%
CVAC Cure Vac N.V.	$990M	$799,000 0.0% of portfolio	148,284	Q3 2025 Reduced 28.14%
CYTK Cytokinetics Inc	$6.25B	$747,000 0.0% of portfolio	13,603	Q3 2025 Reduced 28.72%
ASND Ascendis Pharma A/S	$11.4B	$712,000 0.0% of portfolio	3,586	Q3 2025 Reduced 50.1%
ARWR Arrowhead Pharmaceuticals, Inc.	$4.37B	$700,000 0.0% of portfolio	20,301	Q3 2025 New
SRRK Scholar Rock Holding Corp	$1.95B	$690,000 0.0% of portfolio	18,490	Q3 2025 Reduced 86.43%
ABEO Abeona Therapeutics Inc.	$26.5M	$667,000 0.0% of portfolio	126,384	Q3 2025 New

GOSS Gossamer Bio, Inc.	$255M	$654,000 0.0% of portfolio	248,818	Q3 2025 Added 338.0%
VNDA Vanda Pharmaceuticals Inc.	$246M	$610,000 0.0% of portfolio	122,327	Q3 2025 Reduced 25.48%
ATXS Astria Therapeutics, Inc.	$191M	$598,000 0.0% of portfolio	82,925	Q3 2025 Added 0.64%
ALLO Allogene Therapeutics, Inc.	$177M	$575,000 0.0% of portfolio	463,898	Q3 2025 New
PHVS Pharvaris N.V.	$795M	$571,000 0.0% of portfolio	22,886	Q3 2025 New
DAWN Day One Biopharmaceuticals, Inc.	$646M	$549,000 0.0% of portfolio	77,972	Q3 2025 Reduced 4.1%
BDTX Black Diamond Therapeutics, Inc.	$153M	$530,000 0.0% of portfolio	143,643	Q3 2025 Added 702.47%
DYN Dyne Therapeutics, Inc.	$975M	$526,000 0.0% of portfolio	41,587	Q3 2025 Reduced 91.83%
RNA Avidity Biosciences, Inc.	$3.69B	$504,000 0.0% of portfolio	11,577	Q3 2025 Reduced 95.12%

CDXS Codexis, Inc.	$108M	$424,000 0.0% of portfolio	173,805	Q3 2025 New
TRDA Entrada Therapeutics, Inc.	$266M	$414,000 0.0% of portfolio	71,548	Q3 2025 New
EDIT Editas Medicine, Inc.	$179M	$403,000 0.0% of portfolio	116,179	Q3 2025 Added 5.51%
ABCL Ab Cellera Biologics Inc.	$1.05B	$384,000 0.0% of portfolio	76,483	Q3 2025 Added 49.75%
MGNX Macrogenics Inc	$94.6M	$377,000 0.0% of portfolio	222,200	Q3 2025 Added 121.07%
GLUE Monte Rosa Therapeutics, Inc.	$671M	$372,000 0.0% of portfolio	50,213	Q3 2025 New
RYTM Rhythm Pharmaceuticals, Inc.	$5.54B	$362,000 0.0% of portfolio	3,585	Q3 2025 Reduced 85.23%
VCYT Veracyte, Inc.	$2.82B	$275,000 0.0% of portfolio	8,035	Q3 2025 Reduced 94.86%
RCUS Arcus Biosciences, Inc.	$1.45B	$270,000 0.0% of portfolio	19,871	Q3 2025 Reduced 61.28%
KALV Kal Vista Pharmaceuticals, Inc.	$328M	$254,000 0.0% of portfolio	21,100	Q3 2025 Reduced 17.96%
VIR Vir Biotechnology, Inc.	$747M	$191,000 0.0% of portfolio	33,524	Q3 2025 Reduced 7.54%
CRVS Corvus Pharmaceuticals, Inc.	$408M	$183,000 0.0% of portfolio	25,575	Q3 2025 New
IOVA Iovance Biotherapeutics, Inc.	$390M	$165,000 0.0% of portfolio	76,209	Q3 2025 Added 37.39%
LIFE A Tyr Pharma Inc	$53.2M	$154,000 0.0% of portfolio	83,312	Q3 2025 Added 445.02%
CGEM Cullinan Oncology, Inc.	$390M	$151,000 0.0% of portfolio	25,619	Q3 2025 Added 1.14%
CAPR Capricor Therapeutics, Inc.	$137M	$115,000 0.0% of portfolio	15,945	Q3 2025 Added 48.56%
AKBA Akebia Therapeutics, Inc.	$313M	$105,000 0.0% of portfolio	39,126	Q3 2025 Reduced 82.14%
FDMT 4 D Molecular Therapeutics, Inc.	$351M	$85,000 0.0% of portfolio	10,100	Q3 2025 Reduced 52.21%
PMVP Pmv Pharmaceuticals, Inc.	$63M	$78,000 0.0% of portfolio	55,718	Q3 2025 Reduced 91.4%
CCCC C4 Therapeutics, Inc.	$121M	$26,000 0.0% of portfolio	11,863	Q3 2025 Reduced 86.74%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	34,219	Q3 2025 Reduced 40.44%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.